Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2020 | 03-2020 | 12-2019 | 09-2019 | 06-2019 | |
| Cost of Goods | N/A | N/A | 307 | N/A | N/A |
| Gross Profit | N/A | N/A | -307 | N/A | N/A |
| Operating Expenses | 3,683 | 3,352 | 29,342 | 5,258 | 7,174 |
| Operating Income | -3,683 | -3,352 | -29,342 | -5,258 | -7,174 |
| Interest Expense | 339 | 339 | 293 | 207 | 202 |
| Other Income | -66 | 457 | 42 | 199 | -83 |
| Pre-tax Income | -4,088 | -3,234 | -29,593 | -5,265 | -7,459 |
| Income Tax | N/A | N/A | 13 | -80 | 472 |
| Net Income Continuous | -4,088 | -3,234 | -29,605 | -5,185 | -7,931 |
| Minority Interests | -129 | N/A | N/A | N/A | N/A |
| Net Income | $-3,959 | $-3,234 | $-29,556 | $-5,185 | $-7,931 |
| EPS Basic Total Ops | -4.00 | -3.20 | -36.00 | -6.00 | -10.00 |
| EPS Basic Continuous Ops | -4.30 | -3.40 | -36.17 | -6.47 | -9.90 |
| EPS Diluted Total Ops | -4.00 | -3.20 | -36.00 | -6.00 | -10.00 |
| EPS Diluted Continuous Ops | -4.30 | -3.40 | -36.17 | -6.47 | -9.90 |
| EBITDA(a) | $-3,683 | $-3,352 | $-29,257 | $-5,153 | $-7,036 |